Morris R W, Brubaker L H, Kardinal C G, Carolla R L, Perry M C
Cancer Clin Trials. 1979 Spring;2(1):37-41.
The combination of adriamycin and cis-dichlorodiammineplatinum (DDP) was evaluated in 20 patients with nonresectable and metastatic carcinoma of the lung. Both drugs were administered at a dosage of 60 mg/m2 intravenously every 3 weeks. The overall objective response rate was 40% (eight of 20 patients) with two complete responses (CR) and six partial responses (PR). Four of eight patients with small cell carcinoma responded (1 CR and 3 PR) and four of 12 patients with nonsmall cell carcinoma responded (1 CR and 3 PR). The median duration of response was greater than 36 weeks. The median survival of responders was 54 weeks. Nausea and vomiting were major side effects but rarely lasted longer than 2 days. Renal and bone marrow toxicities were generally minimal and controlled by dosage reduction. However, there was one death secondary to severe myelosuppression.
对20例不可切除的转移性肺癌患者评估了阿霉素和顺二氯二氨铂（DDP）联合治疗的效果。两种药物均以60mg/m²的剂量静脉注射，每3周一次。总有效率为40%（20例患者中有8例），其中完全缓解（CR）2例，部分缓解（PR）6例。8例小细胞癌患者中有4例有反应（1例CR和3例PR），12例非小细胞癌患者中有4例有反应（1例CR和3例PR）。中位缓解持续时间超过36周。有反应者的中位生存期为54周。恶心和呕吐是主要副作用，但很少持续超过2天。肾毒性和骨髓毒性一般较小，可通过减少剂量控制。然而，有1例因严重骨髓抑制死亡。
